Sep. 5 at 10:32 AM
$OGEN Oragenics has been a textbook micro-cap biotech for years — dilutions, reverse splits, and a reputation for financial survival over scientific progress.
But 2025 may mark a turning point:
✅ New leadership (CEO Janet Huffman)
✅ Partnerships with top concussion researchers
✅ Phase 1/2 trial in Australia for ONP-001 (mTBI) — “first patient dosed” expected by end of Q3
✅ Collaboration with BrainBox Solutions to integrate diagnostics + therapeutics
Meanwhile, trading data shows structural suppression:
📌 68% of August trading occurred off-exchange (dark pools >70%)
📌 31% of daily trades short
📌 Every rally attempt met with “sell into strength”
This sets up a classic asymmetric scenario:
👉 Downside: limited so long as
$1.00 support holds
👉 Upside: catalyst-driven breakout to
$2.00–
$2.50, with potential short-squeeze risk above
$3.00
📊 Read the full analysis here: img1.wsimg.com/blobby/go/1f...
